Abstract

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Musinsky J, Noy A. Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient. HIV & AIDS Review. International Journal of HIV-Related Problems. 2021;20(3):223-225. doi:10.5114/hivar.2021.109264. APA Musinsky, J., & Noy, A. (2021). Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient. HIV & AIDS Review. International Journal of HIV-Related Problems, 20(3), 223-225. https://doi.org/10.5114/hivar.2021.109264 Chicago Musinsky, Jacob, and Ariela Noy. 2021. "Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient". HIV & AIDS Review. International Journal of HIV-Related Problems 20 (3): 223-225. doi:10.5114/hivar.2021.109264. Harvard Musinsky, J., and Noy, A. (2021). Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient. HIV & AIDS Review. International Journal of HIV-Related Problems, 20(3), pp.223-225. https://doi.org/10.5114/hivar.2021.109264 MLA Musinsky, Jacob et al. "Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient." HIV & AIDS Review. International Journal of HIV-Related Problems, vol. 20, no. 3, 2021, pp. 223-225. doi:10.5114/hivar.2021.109264. Vancouver Musinsky J, Noy A. Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient. HIV & AIDS Review. International Journal of HIV-Related Problems. 2021;20(3):223-225. doi:10.5114/hivar.2021.109264.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call